Views

Payer Perceptions of the Inflation Reduction Act

Lumanity convened medical and pharmacy directors from six large national and regional US payers with at least 25% Medicare business to share their perspectives on both the Maximum Fair Price (MFP) drug price negotiation and Part D redesign components of the IRA. Read the six key insights from our panel.

View Aug 28, 2023

Widespread Mental Health Provider Shortages Demand Innovative Options

View Aug 25, 2023

Policy Initiatives Can Improve Access to Prescription Digital Therapeutics

View Aug 25, 2023

The Transformative Potential of Digital Therapeutics in Mental Health Care Delivery

View Aug 24, 2023

Inflation Reduction Act (IRA): The Importance of Scenario Planning

View Aug 17, 2023

Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study

In partnership with Myovant Sciences, Martha Gauthier and Brooke Witherspoon of Lumanity’s Patient-Centered Outcomes group recently authored a manuscript characterizing the experience of living with endometriosis from a patient perspective.

View Jul 27, 2023

Learnings from the Latest EUnetHTA 21 HTD Meeting

View Jul 21, 2023

Comparison of Raw and Regression Approaches to Capturing Change on Patient-reported Outcome Measures

View Jun 29, 2023

Opportunities for Enhanced Communication between Manufacturers and US Payers

View Jun 14, 2023

ISPOR Diaries 2023

View May 19, 2023

Updates on Over the Counter Monograph Reform in the CARES Act

The US FDA finalized administrative orders as deemed by Over the Counter Monograph Reform in the CARES Act, but there is still much work to be done.

View May 10, 2023

The EU HTA Regulation

View Apr 27, 2023

Using Real-World Data in the Health Technology Assessment of Pharmaceuticals

View Apr 20, 2023

FTC Compliance Warning for Product Health Claims

View Apr 17, 2023

Cosmetics Industry Regulatory Updates

View Apr 11, 2023

Is Patient Engagement in Regulatory Decisions at a Tipping Point?

To meet the challenge of meeting the growing expectation from regulators for robust patient experience data that demonstrate the impact new products may have for patients and their quality of life, our industry needs to work closely with the patient community, regulators, and other stakeholders.

View Mar 22, 2023